Kymera Therapeutics, Inc. (KYMR)
$106.68-4.82%Close
SELLBEAR · day 23
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8.8B
- Beta
- 1.98
- P/E (TTM)
- -32.82
- Short % float
- 13.59%
- Days to cover
- 12.0
- SI change
- -5.9%
- 1W
- +0.66%
- 1M
- -6.94%
- vs SPY 1W
- +0.80%
- vs SPY 1M
- -9.44%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 0
- GROWTH
- 19
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-12.9%
REV YoY-
ROE-21.5%
EPS YoY-
ROA-18.2%
GROSS102
OP-334
NET-285
[VALUATION]
P/E TTM-32.82
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B6.94
P/FCF-
EV/EBITDA-29.97
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E5.45
ALTMAN Z-
CURR RATIO9.83
ND/EBITDA-
BETA1.98
Company news
FAQ
- What is LOPJLB’s current signal on KYMR?
- LOPJLB’s latest quantitative signal on Kymera Therapeutics, Inc. (KYMR) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is KYMR in?
- Kymera Therapeutics, Inc. (KYMR) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Kymera Therapeutics, Inc. (KYMR) do?
- Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which …